Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

  • 1 December 2018 to 31 March 2019
  • Awards: Pump-priming Awards

Diabetes is associated with adverse clinical outcomes following myocardial infarction (MI) as well as greater myocardial fibrosis and impaired systolic and diastolic function. The mechanisms behind these effects are poorly understood and there are no specific immunomodulatory therapeutic options for affected patients. The local innate immune response following MI controls cardiac remodelling and could in principle be therapeutically targeted in the days following the event.  Furthermore, metabolic reprogramming towards glycolysis in activated monocytes/macrophages is essential for their polarization to an inflammatory phenotype and can be assessed non-invasively following MI with hyperpolarized [1-13C]pyruvate MRI.

This BHF CRE pilot project will develop methods and seek discovery data in this area, to underpin the design of future studies on the effect of diabetic hyperglycaemia on myocardial immune cell immunometabolic function in mice. The research has clear potential links to future human experiments using hyperpolarized MRI to study immune responses following MI.

This project may highlight new therapeutic targets in myocardial infarction in patients with diabetes.

The project is led by Dr Andrew Lewis, Clinical Researcher, OCMR, Oxford BHF CRE